We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$911M
AUM Growth
-$47.6M
Cap. Flow
-$18.7M
Cap. Flow %
-2.05%
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$18.3M
2
MCK icon
McKesson
MCK
+$8.31M
3
COO icon
Cooper Companies
COO
+$7.22M
4
ABT icon
Abbott
ABT
+$7.18M
5
CI icon
Cigna
CI
+$6.56M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$32.2M
2
JNJ icon
Johnson & Johnson
JNJ
+$17.7M
3
MDT icon
Medtronic
MDT
+$9.37M
4
PFE icon
Pfizer
PFE
+$6.91M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$6.48M

Sector Composition

Rank Sector Weight
1 Healthcare 95.19%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
76
Intellia Therapeutics
NTLA
$1.68B
$1.8M 0.2%
50,000
– –
IGMS
77
DELISTED
IGM Biosciences
IGMS
$1.62M 0.18%
95,000
+45,000
+90% +$931K
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$775M
$1.55M 0.17%
115,759
-6,749
-6% -$107K
ESPR
79
DELISTED
Esperion Therapeutics
ESPR
$1.5M 0.17%
900,000
– –
ALLO icon
80
Allogene Therapeutics
ALLO
$749M
$1.49M 0.16%
300,000
-40,000
-12% -$257K
MRSN
81
DELISTED
Mersana Therapeutics
MRSN
$1.4M 0.15%
14,000
-2,000
-13% -$281K
EPIX
82
DELISTED
ESSA Pharma
EPIX
$1.05M 0.12%
356,500
-18,500
-5% -$54.4K
STXS icon
83
Stereotaxis
STXS
$146M
$953K 0.1%
493,618
-303,712
-38% -$683K
AXSM icon
84
Axsome Therapeutics
AXSM
$11.4B
$908K 0.1%
+15,000
New +$985K
NKTX icon
85
Nkarta
NKTX
$164M
$680K 0.07%
200,000
– –
SGMO
86
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$534K 0.06%
314,157
-505,843
-62% -$1.44M
RPID icon
87
Rapid Micro Biosystems
RPID
$86.8M
$165K 0.02%
127,152
-172,848
-58% -$225K
IONS icon
88
Ionis Pharmaceuticals
IONS
$9.32B
– –
-50,000
Closed -$1.89M
JNJ icon
89
Johnson & Johnson
JNJ
$625B
– –
-100,000
Closed -$17.7M
LLY icon
90
Eli Lilly
LLY
$1.09T
– –
-88,000
Closed -$32.2M
NKTR icon
91
Nektar Therapeutics
NKTR
$2.53B
– –
-36,667
Closed -$1.24M
NVST icon
92
Envista
NVST
$4.58B
– –
-163,800
Closed -$5.52M
PHAT icon
93
Phathom Pharmaceuticals
PHAT
$698M
– –
-235,210
Closed -$2.64M
TDOC icon
94
Teladoc Health
TDOC
$1.24B
– –
-130,000
Closed -$3.07M
GTHX
95
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-370,000
Closed -$2.01M
OSH
96
DELISTED
Oak Street Health, Inc.
OSH
– –
-250,000
Closed -$5.38M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rhenman & Partners Asset Management held 97 positions worth $911M, down 5% from $958M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2023 filing shows 4 new, 33 increased, 45 reduced and 9 closed positions. Its largest new stake was Viking Therapeutics: 180,000 shares worth $3.12M. The largest sale was Eli Lilly, an estimated $32.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q1 2023 buy was Viking Therapeutics: 180,000 shares worth $3.12M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q1 2023, an estimated $18.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2023 reduction was Medtronic, cutting an estimated $9.37M.
  • Rhenman & Partners Asset Management fully exited Eli Lilly in Q1 2023, selling an estimated $32.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $911M portfolio in Q1 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 9 in Q1 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 5% quarter-over-quarter to $911M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.